

Ana Ruiz Casado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6067191/publications.pdf>

Version: 2024-02-01

52
papers

1,337
citations

566801

15
h-index

344852

36
g-index

53
all docs

53
docs citations

53
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
2	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	0.8	177
3	Exercise and the Hallmarks of Cancer. <i>Trends in Cancer</i> , 2017, 3, 423-441.	3.8	124
4	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. <i>Cancer</i> , 2003, 98, 832-840.	2.0	97
5	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349.	0.6	89
6	Progress in the clinical development of new marine-derived anticancer compounds. <i>Anti-Cancer Drugs</i> , 2004, 15, 321-329.	0.7	79
7	Cancer-related Fatigue in Breast Cancer Survivors: A Review. <i>Clinical Breast Cancer</i> , 2021, 21, 10-25.	1.1	74
8	Physical Inactivity and Low Fitness Deserve More Attention to Alter Cancer Risk and Prognosis. <i>Cancer Prevention Research</i> , 2015, 8, 105-110.	0.7	67
9	EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 233-240.	2.0	47
10	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3889.	1.0	35
11	Validity of the Physical Activity Questionnaires IPAQ-SF and GPAQ for Cancer Survivors: Insights from a Spanish Cohort. <i>International Journal of Sports Medicine</i> , 2016, 37, 979-985.	0.8	31
12	Exercise prehabilitation program for patients under neoadjuvant treatment for rectal cancer: A pilot study. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 20.	0.3	25
13	Interstitial Granulomatous Drug Reaction to Sorafenib. <i>Archives of Dermatology</i> , 2011, 147, 1119.	1.7	19
14	Physical activity levels are low in patients with pulmonary hypertension. <i>Annals of Translational Medicine</i> , 2018, 6, 205-205.	0.7	19
15	Objectively Assessed Physical Activity Levels in Spanish Cancer Survivors. <i>Oncology Nursing Forum</i> , 2014, 41, E12-E20.	0.5	16
16	Pulmonary toxicity of 5-fluoracil and oxaliplatin. <i>Clinical and Translational Oncology</i> , 2006, 8, 624-624.	1.2	15
17	Prevalence and correlates of cancer-related fatigue in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 6523-6534.	1.0	15
18	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. <i>Cancers</i> , 2020, 12, 657.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Concurrent Exercise Interventions in Breast Cancer Survivors with Cancer-related Fatigue. <i>International Journal of Sports Medicine</i> , 2020, 41, 790-797.	0.8	14
20	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 739-746.	1.0	12
21	Clinical outcomes of FOLFIRINOX and gemcitabine+nab paclitaxel for metastatic pancreatic cancer in the real world setting. <i>Clinical and Translational Oncology</i> , 2021, 23, 812-819.	1.2	11
22	Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 42.	0.3	9
23	Cardiorespiratory fitness and adiposity in breast cancer survivors: is meeting current physical activity recommendations really enough?. <i>Supportive Care in Cancer</i> , 2018, 26, 2293-2301.	1.0	7
24	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. <i>Cancers</i> , 2020, 12, 2259.	1.7	6
25	Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. <i>Cancers</i> , 2021, 13, 4514.	1.7	6
26	Clinical audit of multidisciplinary care at a medium-sized hospital in Spain. <i>World Journal of Surgical Oncology</i> , 2014, 12, 53.	0.8	5
27	Regular physical activity: a little is good, but is it good enough?. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 1099-1101.	2.2	4
28	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. <i>Bone Marrow Transplantation</i> , 2001, 27, 117-123.	1.3	3
29	Life-threatening adverse drug reaction to paclitaxel. Postmarketing surveillance. <i>Clinical and Translational Oncology</i> , 2006, 8, 60-61.	1.2	3
30	Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report. <i>Annals of the Royal College of Surgeons of England</i> , 2017, 99, e225-e226.	0.3	3
31	Erysipeloid rash: A rare adverse event induced by gemcitabine. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 1024.	0.3	3
32	Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. <i>British Journal of Cancer</i> , 2022, 126, 874-880.	2.9	3
33	An autopsy case of acute pulmonary toxicity related to irinotecan. <i>Clinical and Translational Oncology</i> , 2008, 10, 597-598.	1.2	2
34	Lengua geográfica inducida por inhibidores de la angiogénesis. <i>Revista Clinica Espanola</i> , 2018, 218, 501-502.	0.2	2
35	A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. <i>ESMO Open</i> , 2020, 5, e000850.	2.0	2
36	First-line treatment with panitumumab plus FOLFIRI in elderly patients with <i>RAS/BRAF</i> wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3618-TPS3618.	0.8	2

#	ARTICLE	IF	CITATIONS
37	474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2020, 31, S442-S443.	0.6	1
38	Some unanswered questions about older adults with metastatic pancreatic cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1032-1033.	0.5	1
39	Enteritis inducida por quimioterapia: experiencia institucional y revisión bibliográfica. <i>Revista Clínica Española</i> , 2019, 219, 165-167.	0.2	1
40	Threats for sustainability of multidisciplinary working. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1291-1297.	0.3	1
41	Superficial Thrombophlebitis As An Exceptional Complication Of A Scrotal Arteriovenous Malformation. <i>Clinical and Translational Oncology</i> , 2007, 9, 59-59.	1.2	0
42	Cancer-related fatigue in breast cancer survivors: more evidence for a physiological substrate. <i>Annals of Oncology</i> , 2016, 27, vi518.	0.6	0
43	Geographic tongue induced by angiogenesis inhibitors. <i>Revista Clínica Española</i> , 2018, 218, 501-502.	0.3	0
44	POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers. <i>Annals of Oncology</i> , 2019, 30, v221.	0.6	0
45	1873P Cancer-related fatigue: Are we evaluating it?. <i>Annals of Oncology</i> , 2020, 31, S1067-S1068.	0.6	0
46	471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score. <i>Annals of Oncology</i> , 2020, 31, S441.	0.6	0
47	Liver metastases of colon cancer: New therapeutic approaches. <i>Neoadjuvant chemotherapy. Oncologia</i> , 2006, 29, .	0.0	0
48	Cancer-related fatigue in cancer survivors (CS) with no active treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 238-238.	0.8	0
49	Cardio-respiratory fitness and functional performance in patients with a recent diagnosis of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 804-804.	0.8	0
50	RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15151-e15151.	0.8	0
51	Tratamiento de las metástasis hepáticas de cáncer colorrectal con y-90: el problema es la toxicidad. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 67-68.	0.0	0
52	Treatment of colorectal liver metastases with y-90: the problem is the toxicity. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 67-68.	0.1	0